MAO-B-IN-4 (Compound 26) is a reversible monoamine oxidase B (MAO-B) inhibitor with potent in vitro activity, characterized by an IC50 value of 9 nM. This orally active compound exhibits favorable metabolic stability, a satisfactory safety profile, and effective brain permeability. Demonstrating antidepressant effects in rodent models, MAO-B-IN-4 is suitable for research into Alzheimer's disease [1].

Lysyl Hydroxylase 2-IN-2 (compound 13) is a potent inhibitor of Lysyl Hydroxylase 2 (LH2), exhibiting an IC50 of approximately 500 nM. It effectively inhibits cell migration in 344SQ WT cells without affecting the migration of LH2 knockout cells [1].

MAO-B-IN-22 (compound 6h) represents a powerful MAO-B inhibitor, boasting an IC50 value of 0.014 μM, and exhibits high antioxidant activity alongside effective metal-chelating properties. It also demonstrates adequate BBB permeability and notable neuroprotective effects [1].

J-147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.

OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.